Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290224 · ClinicalTrials.gov registry record · Phase 2
MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01290224: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01290224 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01290224, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Scrambler therapy may help relieve pain from peripheral neuropathy caused by chemotherapy. PURPOSE: This phase II trial is studying how well MC5-A scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy
Interventions
- OTHER questionnaire administration
- OTHER scrambler therapy
- PROCEDURE sham intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290224
The ClinicalTrials.gov registry entry for NCT01290224 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which questionnaire administration is the first listed.
NCT01290224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290224 about?
NCT01290224 is a clinical study titled "MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy". RATIONALE: Scrambler therapy may help relieve pain from peripheral neuropathy caused by chemotherapy. PURPOSE: This phase II trial is studying how well MC5-A scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy
What is the current status of trial NCT01290224?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-02. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01290224?
The interventions under investigation include: questionnaire administration (OTHER), scrambler therapy (OTHER), sham intervention (PROCEDURE).
Who is sponsoring clinical trial NCT01290224?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.